Select
Press releases
Paris (France) and Lausanne (Switzerland), 04 February 2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Paris (France), 01 February 2010
Ipsen’s fourth quarter and full year 2009 sales
• +7.6% drug sales growth at constant currency, in line with objectives • Strong and continued specialty care dynamics: +13.9% at constant currency • Sustained growth in international markets: +12.1% at constant currency • Acceleration of specialty care sales growth in fourth quarter 2009, up 16.1% year-on-year
• +7.6% drug sales growth at constant currency, in line with objectives • Strong and continued specialty care dynamics: +13.9% at constant currency • Sustained growth in international markets: +12.1% at constant currency • Acceleration of specialty care sales growth in fourth quarter 2009, up 16.1% year-on-year
Paris (France) and Laguna Niguel (California, USA), 21 January 2010
Ipsen and Inspiration Biopharmaceuticals enter into partnership to create a world leading hemophilia franchise
• Portfolio covers all major hemophilia markets and worldwide sales could exceed $1.0 billion by 2020 • Following the exclusive in-licensing of Ipsen’s OBI-1 alongside its own IB1001, Inspiration’s portfolio now includes two recombinant protein products ready to enter Phase III in 2010 and two earlier development compounds for the treatment of bleeding disorders • Ipsen to acquire initial 20% stake in Inspiration for $85 million with the potential to increase ownership up to 47% through up to $174 million in additional milestone-based funding.
• Portfolio covers all major hemophilia markets and worldwide sales could exceed $1.0 billion by 2020 • Following the exclusive in-licensing of Ipsen’s OBI-1 alongside its own IB1001, Inspiration’s portfolio now includes two recombinant protein products ready to enter Phase III in 2010 and two earlier development compounds for the treatment of bleeding disorders • Ipsen to acquire initial 20% stake in Inspiration for $85 million with the potential to increase ownership up to 47% through up to $174 million in additional milestone-based funding.
Paris (France), 19 January 2010
“Sensory Systems: smell, taste, touch, hearing and vision”
Fourth meeting in the “Biological Complexity” series jointly organised by Fondation Ipsen and the Salk Institute for Biological Studies
Fourth meeting in the “Biological Complexity” series jointly organised by Fondation Ipsen and the Salk Institute for Biological Studies
